GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Equity-to-Asset

Roquefort Therapeutics (LSE:ROQ) Equity-to-Asset : 0.85 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Roquefort Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was £4.89 Mil. Roquefort Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was £5.75 Mil.

The historical rank and industry rank for Roquefort Therapeutics's Equity-to-Asset or its related term are showing as below:

LSE:ROQ' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.85   Med: 0.9   Max: 0.93
Current: 0.85

During the past 4 years, the highest Equity to Asset Ratio of Roquefort Therapeutics was 0.93. The lowest was 0.85. And the median was 0.90.

LSE:ROQ's Equity-to-Asset is ranked better than
74.34% of 1485 companies
in the Biotechnology industry
Industry Median: 0.68 vs LSE:ROQ: 0.85

Roquefort Therapeutics Equity-to-Asset Historical Data

The historical data trend for Roquefort Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Equity-to-Asset Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
0.90 0.93 0.90 0.85

Roquefort Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Equity-to-Asset Get a 7-Day Free Trial 0.93 0.91 0.90 0.81 0.85

Competitive Comparison of Roquefort Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Roquefort Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roquefort Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roquefort Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Roquefort Therapeutics's Equity-to-Asset falls into.


;
;

Roquefort Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Roquefort Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=4.889/5.751
=

Roquefort Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=4.889/5.751
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roquefort Therapeutics  (LSE:ROQ) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Roquefort Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Roquefort Therapeutics Business Description

Traded in Other Exchanges
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines

No Headlines